Kenya will begin rolling out a groundbreaking HIV-prevention drug in March that offers near-complete protection with just two injections a year.
The drug, lenacapavir, manufactured by Gilead Sciences, reduces the risk of HIV transmission by more than 99.9 percent.
Kenya has received an initial 21,000 doses through a Global Fund agreement, with another 12,000 expected by April. The first phase will cover 15 counties.
The rollout comes as African countries adjust to shifting U.S. foreign aid priorities under President Donald Trump.
Eastern and southern Africa remain the hardest-hit regions, accounting for more than half of the 40.8 million people living with HIV globally.
Source: DW Africa
